The COVID-19 pandemic placed unprecedented demands on global healthcare systems, regulators and researchers. Vaccines were developed, approved and rolled out at exceptional speed.
While this should be seen as a success, the pace of development also brought into focus an essential component of pharmacovigilance: the need for robust, ongoing monitoring of vaccine safety in clinical practice.
Our recently study: Safety and utilisation of AZD1222 (ChAdOx1 nCoV-19) COVID-19 vaccine: a UK post-authorisation active surveillance study, provides one of the most comprehensive real-world safety evaluations of the AstraZeneca COVID-19 vaccine in the UK to date.
Check out the rest of the feature here
